NI-RADS预测头颈部鳞状细胞癌的诊断准确性:系统评价与Meta分析
该系统评价与Meta分析纳入12项研究,评估NI-RADS在治疗后头颈部鳞状细胞癌患者中识别复发的诊断准确性。汇总敏感度为0.69(95%CI 0.59-0.79),特异度为0.94(95%CI 0.89-0.97);NI-RADS 1-3类的复发率分别为0.03(95%CI 0.02-0.05)、0.13(95%CI 0.10-0.15)和0.77(95%CI 0.73-0.81)。NI-RADS特异度高但敏感度中等,3类恶性率显著高于2类。
要点
- NI-RADS汇总特异度0.94(95%CI 0.89-0.97),敏感度0.69(95%CI 0.59-0.79)。
- NI-RADS 1-3类复发率分别为0.03、0.13和0.77(95%CI分别为0.02-0.05、0.10-0.15、0.73-0.81)。
- 3类恶性率显著高于2类。
核心结论
- NI-RADS在头颈部鳞状细胞癌治疗后患者中显示高特异度但中等敏感度,3类恶性率显著高于2类。
研究设计与样本
- 系统评价与Meta分析,纳入12项研究,检索2016年6月起发表的文献,以病理结果和/或随访为参考标准,采用HSROC模型汇总诊断准确性,使用QUADAS-2工具评价研究质量。
诊断标准与关键数值
- 总体汇总敏感度0.69(95%CI 0.59-0.79),特异度0.94(95%CI 0.89-0.97)。
- 原发部位汇总敏感度0.67(95%CI 0.53-0.78),特异度0.95(95%CI 0.90-0.97)。
- 淋巴结部位汇总敏感度0.64(95%CI 0.44-0.80),特异度0.99(95%CI 0.98-0.99)。
- NI-RADS 1类复发率0.03(95%CI 0.02-0.05),2类0.13(95%CI 0.10-0.15),3类0.77(95%CI 0.73-0.81)。
临床应用与阅片要点
- NI-RADS 3类复发率0.77(95%CI 0.73-0.81),显著高于2类的0.13(95%CI 0.10-0.15)。
- NI-RADS汇总特异度0.94(95%CI 0.89-0.97),敏感度0.69(95%CI 0.59-0.79)。
局限性
- Meta回归显示分析类型(按人 vs 按部位)和部位数量(≤200 vs >200)是与异质性相关的显著因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study aimed to assess the diagnostic performance of NI-RADS for the prediction of recurrence in patients treated for Head and Neck Squamous Cell Carcinoma (HNSCC).
METHODS: A literature search was conducted using various databases to identify relevant articles published from June 2016 onwards. We included studies reporting the diagnostic accuracy of NI-RADS in distinguishing recurrence in patients undergoing imaging surveillance, with pathologic results and/or follow-up as the reference standard. Summary estimates of diagnostic accuracy in terms of sensitivity, specificity, positive likelihood ratio (LR +), negative likelihood ratio (LR -), and diagnostic odds ratio (DOR) were calculated with the hierarchical summary receiver operating characteristic (HSROC) model. Meta-regression and subgroup analyses were conducted to investigate different clinical settings. Study quality was evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2 tool.
RESULTS: A total of 12 studies were included in the current meta-analysis. The pooled sensitivity and specificity were 0.69 (95% CI 0.59-0.79) and 0.94 (95% CI 0.89-0.97), respectively. For the primary site, the pooled summary estimates were 0.67 (95% CI 0.53-0.78) and 0.95 (95% CI 0.90-0.97), for the nodal sites were 0.64 (95% CI 0.44-0.80) and 0.99 (95% CI 0.98-0.99), respectively. The recurrence rate for NI-RADS categories 1-3 was 0.03 (95% CI 0.02-0.05), 0.13 (95% CI 0.10-0.15), and 0.77 (95% CI 0.73-0.81). Meta-regression revealed that the type of analysis (per person vs. per site) and number of sites (≤ 200 vs. > 200) were significant factors associated with heterogeneity.
CONCLUSIONS: NI-RADS demonstrated high specificity but moderate sensitivity in patients after treatment for HNSCC. Summary estimates showed a significantly higher malignancy rate for NI-RADS category 3 compared to category 2.
引用
- Li W, Sun Y, Shang W, et al. Diagnostic accuracy of NI-RADS for prediction of head and neck squamous cell carcinoma: a systematic review and meta-analysis. Radiol Med. 2023. PMID: 37904037. doi:10.1007/s11547-023-01742-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。